Immuneering (IMRX) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 31, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 1 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about IMRX filings

Are insiders buying or selling Immuneering Corp (IMRX) stock?

Neither. Immuneering Corp (IMRX) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IMRX recently?

None. No member of Congress disclosed a IMRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IMRX smart-money data?

This summary uses filings available on Oct 31, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on IMRX

Lean long1 source:
- Insiders
Neutral1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
- Brett Matthew Hall, bought $25K, open market, filed Jun 16
- Benjamin J. Zeskind, bought $10.9K, open market, filed Jun 24
Lean long · thin2 buys · $36K
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
- State Street, trimmed -$14.4M, holdings at Mar 31
- BlackRock, added +$13.9M, holdings at Jun 30
Neutral · thin1 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about IMRX filings

Are insiders buying or selling Immuneering Corp (IMRX) stock?

Neither. Immuneering Corp (IMRX) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IMRX recently?

None. No member of Congress disclosed a IMRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IMRX smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$13.9MSells/Trims$14.4M

Buys/Adds (1)

BR
BlackRock
Q2 2026 13F
$13.9M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (1)

SS
State Street
Q1 2026 13F
$14.4M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Oct 29, 2026

Earnings came in 21.0% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Oct 29, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.37-21.03% miss

-$0.31 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

Estimated report: Nov 11, 2026, in 11 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Oct 29, 2026	-$0.37est. -$0.31	-21.03%miss	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2026Reported Aug 5, 2026	-$0.27est. -$0.27	-0.53%in line	$0.00Yahoo Finance	No year-ago quarter
Mar 31, 2026Reported May 15, 2026	-$0.21est. -$0.25	+16.67%beat	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2025Reported Mar 6, 2026	-$0.18est. -$0.31	+42.25%beat	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2023Reported Mar 1, 2024	Not on file	No estimate	$0.00 · FYSEC filing	No year-ago quarter
Sep 30, 2023Reported Nov 9, 2023	Not on file	No estimate	$0.00SEC filing	-100.0%from $38.4K
Jun 30, 2023Reported Aug 3, 2023	Not on file	No estimate	$0.00SEC filing	-100.0%from $94.4K
Mar 31, 2023Reported May 4, 2023	Not on file	No estimate	$0.00SEC filing	-100.0%from $183.7K

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $3.99
52-wk high: $8.48
High: $4.10
52-wk low: $3.38
Low: $3.87
Prev close: $3.99
Mkt cap: $260.1M
ROE: -52.1%
Beta: 0.46
P/S: 563.6x
P/B: 1.4x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $260M

Valuation

P/S563.62
P/B1.36

Quality

Operating margin0.0%
ROE-52.1%
ROA-32.8%

Growth

Beta0.46

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

35 / 100

RSI 14

53balanced

20D volatility

56%annualized

52-week range

$4.02

$3.38$8.48

20D support

$3.38recent floor

20D resistance

$4.16recent ceiling

Returns

5D +5.5%20D -0.2%60D -8.4%

Price vs moving averages

SMA20 +6.1%SMA50 -6.8%SMA200 -16.5%

Volume pace

1.11xvs prior 20D

Smart money at a glance

Filings to Oct 31, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 1 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about IMRX filings

Are insiders buying or selling Immuneering Corp (IMRX) stock?

Neither. Immuneering Corp (IMRX) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IMRX recently?

None. No member of Congress disclosed a IMRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IMRX smart-money data?

13F: filed up to 45 days late.

Smart money on IMRX

Lean long1 source:
- Insiders
Neutral1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
- Brett Matthew Hall, bought $25K, open market, filed Jun 16
- Benjamin J. Zeskind, bought $10.9K, open market, filed Jun 24
Lean long · thin2 buys · $36K
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
- State Street, trimmed -$14.4M, holdings at Mar 31
- BlackRock, added +$13.9M, holdings at Jun 30
Neutral · thin1 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about IMRX filings

Are insiders buying or selling Immuneering Corp (IMRX) stock?

Neither. Immuneering Corp (IMRX) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IMRX recently?

None. No member of Congress disclosed a IMRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IMRX smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$13.9MSells/Trims$14.4M

Buys/Adds (1)

BR
BlackRock
Q2 2026 13F
$13.9M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (1)

SS
State Street
Q1 2026 13F
$14.4M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Oct 29, 2026

Earnings came in 21.0% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Oct 29, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.37-21.03% miss

-$0.31 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

Estimated report: Nov 11, 2026, in 11 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Oct 29, 2026	-$0.37est. -$0.31	-21.03%miss	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2026Reported Aug 5, 2026	-$0.27est. -$0.27	-0.53%in line	$0.00Yahoo Finance	No year-ago quarter
Mar 31, 2026Reported May 15, 2026	-$0.21est. -$0.25	+16.67%beat	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2025Reported Mar 6, 2026	-$0.18est. -$0.31	+42.25%beat	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2023Reported Mar 1, 2024	Not on file	No estimate	$0.00 · FYSEC filing	No year-ago quarter
Sep 30, 2023Reported Nov 9, 2023	Not on file	No estimate	$0.00SEC filing	-100.0%from $38.4K
Jun 30, 2023Reported Aug 3, 2023	Not on file	No estimate	$0.00SEC filing	-100.0%from $94.4K
Mar 31, 2023Reported May 4, 2023	Not on file	No estimate	$0.00SEC filing	-100.0%from $183.7K

Open: $3.99
52-wk high: $8.48
High: $4.10
52-wk low: $3.38
Low: $3.87
Prev close: $3.99
Mkt cap: $260.1M
ROE: -52.1%
Beta: 0.46
P/S: 563.6x
P/B: 1.4x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $260M

Valuation

P/S563.62
P/B1.36

Quality

Operating margin0.0%
ROE-52.1%
ROA-32.8%

Growth

Beta0.46

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

35 / 100

RSI 14

53balanced

20D volatility

56%annualized

52-week range

$4.02

$3.38$8.48

20D support

$3.38recent floor

20D resistance

$4.16recent ceiling

Returns

5D +5.5%20D -0.2%60D -8.4%

Price vs moving averages

SMA20 +6.1%SMA50 -6.8%SMA200 -16.5%

Volume pace

1.11xvs prior 20D

Immuneering Corp

Smart money at a glance

What do analysts expect?

Questions about IMRX filings

Smart money on IMRX

Questions about IMRX filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 21.0% below what analysts expected.

Estimated report: Nov 11, 2026, in 11 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Immuneering Corp

Smart money at a glance

What do analysts expect?

Questions about IMRX filings

Smart money on IMRX

Questions about IMRX filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 21.0% below what analysts expected.

Estimated report: Nov 11, 2026, in 11 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Immuneering Corp

Overview

Questions about IMRX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Immuneering Corp

Overview

Questions about IMRX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.